Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,764 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type 2 Clear all
Terminated Phase 3 Interventional

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

NCT00411892
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
pioglitazone, inhaled human insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
110
States / cities
Ozark, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

NCT01377844
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
EGT0001442, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Buena Park, California • Los Angeles, California • Santa Ana, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 13, 2026, 5:13 PM EDT
Not listed Not applicable Interventional

Use of a Computer-Assisted Decision Support (CADS) System in Management of Patients With Type 2 Diabetes

NCT01382264
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Computer Assisted Decision Support
Other
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Dorzagliatin and Empagliflozin

NCT03790787
View directory record Official record
Conditions
Patients
Interventions
Empagliflozin, Dorzagliatin
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

NCT00615212
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK376501, Midazolam, Rosiglitazone, Flurbiprofen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 13, 2026, 5:13 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

NCT03566511
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Diazoxide, Placebo
Drug
Lead sponsor
Meredith Hawkins
Other
Eligibility
21 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Diabetic Patient Health Through Assistive-Reading Technology

NCT05337306
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice, Literacy
Interventions
GogyUp Reader
Other
Lead sponsor
GogyUp Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 13, 2026, 5:13 PM EDT
Not yet recruiting Not applicable Interventional

Effect Of Percutaneous Electrical Nerve Field Stimulation on Symptom Control/Nervous System Activity in Patients w/Diabetes Types 1/2

NCT06783504
View directory record Official record
Conditions
Diabetes, Gastroparesis
Interventions
PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION, Sham percutaneous electrical nerve field stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Not applicable Interventional

A National Study of the Chronic Disease Self-Management Program

NCT01845857
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Chronic Disease
Interventions
Chronic Disease Self-Management Workshop
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 3 Interventional

Extension Study for 2993-112

NCT01789957
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AC2993
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
219
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Not applicable Interventional

Targeting Hyaluronan Accumulation Through Exercise in T2DM

NCT04383314
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
10-week exercise program on HA accumulation
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 13, 2026, 5:13 PM EDT
Recruiting Phase 2 Interventional

Improving Coronary Vascular Health in Women

NCT06843902
View directory record Official record
Conditions
HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
Interventions
Health Education, Subspecialty clinic referral
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed No phase listed Observational

Description of Patients With Type 1 Diabetes Treated With Teplizumab

NCT06892002
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teplizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
24
States / cities
Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Not applicable Interventional Results available

A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community

NCT02114814
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes self-management program for Hispanics and their families, General health educational program for Hispanics and their families
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 99 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 13, 2026, 5:13 PM EDT
Completed No phase listed Observational

MiniMed Fit Payload Wear Pediatric Study

NCT07675161
View directory record Official record
Conditions
Diabetes (DM), Diabetes (Insulin-requiring, Type 1 or Type 2), Diabetes in Children, Diabetes in Adolescence
Interventions
MiniMed Fit Payload adhesive components
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Sacramento, California • Santa Barbara, California • Idaho Falls, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Terminated Phase 4 Interventional Results available

Treatment of GLP-1 for Diabetic Bariatric Patients

NCT04624672
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide (1 Mg Dose), Placebo
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics

NCT01147861
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK256073, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Anniston, Alabama • Miami, Florida • Miami Gardens, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 13, 2026, 5:13 PM EDT
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

NCT01427257
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Single Dose PB1023
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Not applicable Interventional

Bronx A1c: Bring it Down for Health

NCT00797888
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
telephonic
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Metabolic Effects of Short-term Walnut Consumption in Subjects With the Metabolic Syndrome

NCT00525629
View directory record Official record
Conditions
Metabolic Syndrome, Type 2 Diabetes, Cardiovascular Disease
Interventions
Walnuts, Control
Dietary Supplement
Lead sponsor
Christos Mantzoros
Other
Eligibility
40 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

NCT00976261
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1614235, Sitagliptin, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 13, 2026, 5:13 PM EDT
Completed Phase 3 Interventional

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00333151
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, rosiglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
71
States / cities
Goodyear, Arizona • Colton, California • Concord, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 13, 2026, 5:13 PM EDT